Explore

Wearable Health Technology Transforms Telemedicine Landscape with Real-Time Data Tracking

Wearable Health Technology Transforms Telemedicine Landscape with Real-Time Data Tracking

Wearable health technology, including smartwatches and other devices, is increasingly being integrated into telemedicine, allowing for the real-time tracking of physiological and behavioral data. These devices monitor activity, heart rate, sleep patterns, and other measurements, providing healthcare providers with continuous information between appointments. This advancement moves beyond traditional video and telephone consultations, expanding into a broader digital healthcare experience that includes remote monitoring, connected medical devices, and artificial intelligence. While these consumer wearable devices offer valuable insights, they are not yet considered medical diagnostic tools, and any concerning readings should be discussed with a healthcare professional. The goal is to enhance patient care by making health information more accessible and efficient, without replacing the critical role of in-person evaluations when necessary.

AI-Driven Automation Transforms Clinical Trial Setup, Reducing Timelines from Months to Days

AI-Driven Automation Transforms Clinical Trial Setup, Reducing Timelines from Months to Days

AI-driven automation is fundamentally changing the landscape of clinical trial setup, significantly reducing the time required for various tasks. Traditionally, processes like protocol drafting, form creation, database builds, and validation could take weeks or even months due to manual handoffs and sequential workflows. With AI, these tasks are now compressed into minutes or days through automated generation and intelligent configuration. This shift allows for a streamlined, parallel process that supports faster decision-making and earlier study execution. Beyond just time savings, this approach introduces new capabilities such as rapid study simulation and near-real-time analytics, enabling research teams to identify potential issues earlier and proceed with greater confidence. This transformation reallocates effort from repetitive build tasks towards enhancing study quality, oversight, and the patient experience, marking a significant advancement in clinical operations.

Pfizer Medical Director Discusses AI's Role in Bridging Clinical Trial Data to Real-World Application

Pfizer Medical Director Discusses AI's Role in Bridging Clinical Trial Data to Real-World Application

Pfizer Medical Director Discusses AI's Role in Bridging Clinical Trial Data to Real-World Application

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

NIH Funding Cuts Lead to Financial Strain and Staff Reductions at Clinical Research Sites

NIH Funding Cuts Lead to Financial Strain and Staff Reductions at Clinical Research Sites

Clinical research sites are experiencing increased operational challenges, with trial complexity identified as the top problem by 41% of sites, up from 35% a year ago. Two-thirds of sites report their teams are overloaded or at risk of burnout, and less than a third find their current workload sustainable, according to WCG’s fourth annual Clinical Research Site Challenges Report. Protocol design is a primary source of difficulty, with 66% of sites rating protocol complexity as a high driver of overall trial difficulty. Sponsor-driven design changes lead to amendments at 78% of sites, consuming a significant portion of study start-up time. Furthermore, NIH funding cuts have exacerbated financial pressures, with nearly two-thirds of sites reporting negative impacts on their financial performance. In response, many sites have implemented hiring freezes or staff reductions, which further intensifies staffing strain, ranked second in the survey at 38%. Contract and budget delays also contribute significantly to...

Dr. Sanish Davis Highlights AI's Transformative Role in Clinical Research

Dr. Sanish Davis Highlights AI's Transformative Role in Clinical Research

Dr. Sanish Davis, Senior Medical Director, Clinical Sciences – Oncology, Takeda, and an Executive Committee Member of the Indian Society for Clinical Research (ISCR), recently shared insights on the expanding role of artificial intelligence (AI) and digital tools in clinical research. In his presentation, 'AI and Digital Tools in Clinical Research,' Dr. Davis explored how these emerging technologies are fundamentally transforming various aspects of clinical trials. He emphasized AI's potential to enhance clinical research processes, improve overall efficiency, and support the advancement of clinical trials from their initial design phases through execution and data management. This discussion was part of PHIR’s First Anniversary Special Live Interaction Session, which convened industry leaders to deliberate on innovation and the future trajectory of the pharmaceutical industry.

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance detailing its patient-centered approach to assessing clinical trial applications that rely on non-clinical safety data generated outside the Organisation for Economic Co-operation and Development (OECD) Mutual Acceptance of Data framework. This guidance, issued on November 4, 2026, aims to support a more risk-proportionate approach to clinical research, thereby advancing the development of new treatments and increasing opportunities for UK patients to participate in trials. While data generated within the OECD framework remains the expected standard, the MHRA will now consider non-OECD data in individual applications, particularly when supported by evidence and the circumstances of the intended patient population.

Roche Partners with Chai Discovery to Integrate AI for Protein Therapeutic Discovery

Roche Partners with Chai Discovery to Integrate AI for Protein Therapeutic Discovery

Roche Partners with Chai Discovery to Integrate AI for Protein Therapeutic Discovery

HBox Seeks Care Coach with AI Interest for Chronic Condition Management

HBox Seeks Care Coach with AI Interest for Chronic Condition Management

HBox, a company focused on revolutionizing healthcare delivery through AI and innovative care solutions, is seeking a Care Coach (Virtual Medical Assistant). This role involves providing empathetic and patient-centered care to individuals with chronic conditions, supporting their care plans, and coaching them on healthy lifestyle choices. Key responsibilities include educating patients on diet, exercise, and medication adherence, offering personalized coaching to achieve health goals, and encouraging the use of vital monitoring tools. The ideal candidate will have a strong interest in the integration of AI technology in healthcare and its potential to enhance care delivery. Proficiency in various Electronic Medical Records (EMR) systems is essential, and bilingual proficiency in Arabic or Spanish is preferred.

Pivotal Technologies Partners with b.well to Enhance Healist.AI with Comprehensive Health Records

Pivotal Technologies Partners with b.well to Enhance Healist.AI with Comprehensive Health Records

Pivotal Technologies, the creator of the AI-powered health app Healist.AI, has announced a partnership with b.well Connected Health. This collaboration will enable Healist.AI users to integrate their complete health records directly into the app, providing a comprehensive view of their health alongside data from wearables and connected devices. b.well Connected Health offers a scalable, FHIR-based platform that unifies health data, solutions, and services. Through this partnership, b.well will access its network of 2.4 million providers, 350 health plans, and hundreds of personal health devices to gather a user's health history, including conditions, medications, lab results, allergies, and immunizations. This data will then undergo a 13-step refinement process to create a usable, longitudinal health record that updates as new information becomes available. The partnership emphasizes trust and safety, with Healist.AI protecting health data to HIPAA security standards and encrypting it in transit and at res...

Healthcare Sector Navigates AI Automation with Focus on Drudgery vs. Judgment Tasks

Healthcare Sector Navigates AI Automation with Focus on Drudgery vs. Judgment Tasks

The healthcare sector is strategically evaluating the implementation of AI automation by distinguishing between tasks that involve 'drudgery' and those requiring 'judgment.' A framework is being used to assess tasks based on how well AI performs them and the degree to which human judgment is necessary. Tasks where AI performs reliably and the manual work is repetitive and low-value, such as searching for values across documents or comparing data, are considered prime candidates for automation. This approach, exemplified by MRO's Prodigy™ for clinical data abstraction, aims to free healthcare professionals from tedious tasks, allowing them to focus on areas that genuinely require their expertise and critical thinking. Conversely, tasks where AI performs well but still necessitate human interpretation or decision-making, or where AI is not yet reliable, are kept under human oversight. The goal is not to eliminate human roles but to redefine them, shifting the focus from manual hunting to applying specialized...

FDA Issues Final Guidance on Prescription Drug Use-Related Software, Clarifying Regulatory Approach for Mobile Apps

FDA Issues Final Guidance on Prescription Drug Use-Related Software, Clarifying Regulatory Approach for Mobile Apps

The U.S. Food and Drug Administration (FDA) released final guidance on October 20, 2026, titled "Regulatory Considerations for Prescription Drug Use-Related Software." This guidance outlines how the FDA intends to apply its drug labeling authorities to software, such as mobile applications, that drug sponsors distribute for use with their prescription drugs. Concurrently, the Obesity Action Coalition (OAC) published new research detailing patient preferences for prescription companion apps, emphasizing the importance of clear medication instructions, data privacy explanations, and patient control over shared health information. The OAC's findings indicate that 86% of surveyed patients would be influenced by FDA review when deciding to use an app, highlighting the significance of regulatory oversight in patient trust and adoption of digital health tools. The FDA's guidance clarifies when such software should be included in official drug information and when drug companies must submit app content to the agen...